Select Page

Leslie Gordon, MD, PhD
Medical Director and Chair, Organizing Committee
Plasma progerin changes with lonafarnib therapy – association with drug effect and extended survival
The Progeria Research Foundation, Brown University, Hasbro Children’s Hospital, Boston Children’s Hospital, and Harvard University


Vicente Andrés, PhD
Scientific Organizing Committee

Novel molecular and cellular mechanisms underlying HGPS
CNIC, Spanish National Cardiovascular Research Center, Madrid, Spain


Abigail Buchwalter, PhD
Assistant Professor

Combined proteome-wide measurements of protein and cell turnover across tissues accounts for the tissue specificity of progeria
Cardiovascular Research Institute and the Department of Physiology at the University of California, San Francisco


Francis Collins, MD, PhD
Racing for progeria cures with RNA and DNA therapies
Director, National Institutes of Health, Bethesda,


Mario Cordero, PhD
Lessons from the inflammasomes in the pathophysiology of Progeria
Biomedical Research and Innovation Institute of Cadiz (INIBICA)


Karima Djabali, PhD


Maria Erikkson, PhD


Roland Foisner, PhD
Endothelial and systemic upregulation of miR-34a-5p fine-tunes senescence in progeria


Jay Humphrey, PhD
Department Chair and Professor of Biomedical Engineering

Evolving vascular phenotypes and cardiovascular consequences in a mouse model of HGPS and its treatment
Department of Biomedical Engineering Yale University


Monica Kleinman, MD
Everolimus plus lonafarnib clinical trial outcomes
Boston Children’s Hospital


Chiara Lanzulo, PhD
Senior tenured researcher

Genome function’s recovery upon pharmacological treatments in Hutchinson Gilford Progeria Syndrome
Institute of Biomedical Technologies (ITB)-CNR
Chromatin and Nuclear architecture Laboratory at Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi”  p/o Policlinico, Padiglione Invernizzi, Milan, Italy


David R. Liu, PhD
Richard Merkin Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, Director of the Chemical Biology and Therapeutic Sciences Program, Core Institute Member and Vice-Chair of the Faculty, Broad Institute. Investigator, Howard Hughes Medical Institute, Thomas Dudley Cabot Professor of the Natural Sciences and Professor of Chemistry & Chemical Biology, Harvard University
Precision Genome Editing and Progeria

Howard Hughes Medical Institute, Broad Institute, Harvard University


Elsa Logarinho, PhD
Junior Researcher

Small-molecule correction of microtubule-dependent genotoxic stress in HGPS cells bypasses progerin-driven cellular phenotypes
Instituto de Biologia Molecular e Celular (IBMC) Instituto de Inovação e Investigação em Saúde (i3S) b.


Tom Misteli, PhD
New cellular pathways and therapeutic approaches in HGPS
National Cancer Institute, National Institutes of Health, Bethesda, MD


Ashwin Prakash, MD
Update on echocardiographic abnormalities in HGPS: follow up data and new deformation measures
Boston Children’s Hospital, Boston, MA